Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic protei…
$3.14-2.48%
报价 2026-11-06
市值
$119.7M
EV
–
PE (TTM)
–
预期 PE
–
52 周区间距高点 -38.8%
$3.09$5.13
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Biotechnology| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| MOLNMolecular Partners AG | $119.7M | -2.5% | – | 0% | – | – | – | |
| HUMAHumacyte, Inc. | $124.5M | +13.3% | +174.1% | -666.8% | – | – | – | |
| NKTXNkarta, Inc. | $123.9M | +10.2% | – | 0% | – | – | – | |
| ZNTLZentalis Pharmaceuticals, Inc. | $122.4M | +0.6% | -22.2% | 0% | – | – | – | |
| CHRSCoherus Oncology, Inc. | $119M | +2.8% | +68.7% | 63.6% | – | – | – | |
| CDXSCodexis, Inc. | $118.3M | +5.9% | +10.1% | 79.5% | – | – | – | |
| OKUROnKure Therapeutics, Inc. | $116M | +13.5% | -28.6% | 0% | – | – | – | |
| NERVMinerva Neurosciences, Inc. | $115.5M | +5.2% | -56.2% | 0% | – | – | – | |
| VYGRVoyager Therapeutics, Inc. | $114.9M | +8.4% | +31.0% | 89.9% | – | – | – | |
| 同行中位数 | – | – | +10.1% | 0% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
报告货币 CHF（非美元）暂无季度数据（首次研究运行后填充）。